Astellas Reports EMA’s Acceptance of MAA for Fezolinetant to Treat Vasomotor Symptoms Associated with Menopause
Shots:
- The EMA has accepted the MAA of fezolinetant for regulatory review to treat VMS in patients associated with menopause
- The MAA was based on the BRIGHT SKY program incl. 3 P-III (SKYLIGHT 1/2/4) trials evaluating fezolinetant in ~2,800 women with VMS at ~180 sites within the US, Canada & EU
- The results from the (SKYLIGHT 1 & 2) trials characterize the efficacy & safety of fezolinetant for the first 12wks, followed by a 40wk. treatment extension period while the (SKYLIGHT 4) safety study further characterizes the long-term safety profile. If EC authorized fezolinetant, it will be a nonhormonal treatment for mod. to sev. vasomotor symptoms associated with menopause
Ref: PRNewswire | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
